• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺病毒载体表达 CRISPR/Cas9 的八个多重引导 RNA 可有效破坏来自不同患者的乙型肝炎病毒基因。

Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.

机构信息

Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Foundation, Shinagawa-ku, Tokyo 141-0021, Japan.

Laboratory of Molecular Genetics, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.

出版信息

Int J Mol Sci. 2021 Sep 29;22(19):10570. doi: 10.3390/ijms221910570.

DOI:10.3390/ijms221910570
PMID:34638909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8508944/
Abstract

Hepatitis B virus (HBV) chronically infects more than 240 million people worldwide, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Genome editing using CRISPR/Cas9 could provide new therapies because it can directly disrupt HBV genomes. However, because HBV genome sequences are highly diverse, the identical target sequence of guide RNA (gRNA), 20 nucleotides in length, is not necessarily present intact in the target HBV DNA in heterogeneous patients. Consequently, possible genome-editing drugs would be effective only for limited numbers of patients. Here, we show that an adenovirus vector (AdV) bearing eight multiplex gRNA expression units could be constructed in one step and amplified to a level sufficient for in vivo study with lack of deletion. Using this AdV, HBV X gene integrated in HepG2 cell chromosome derived from a heterogeneous patient was cleaved at multiple sites and disrupted. Indeed, four targets out of eight could not be cleaved due to sequence mismatches, but the remaining four targets were cleaved, producing irreversible deletions. Accordingly, the diverse X gene was disrupted at more than 90% efficiency. AdV containing eight multiplex gRNA units not only offers multiple knockouts of genes, but could also solve the problems of heterogeneous targets and escape mutants in genome-editing therapy.

摘要

乙型肝炎病毒 (HBV) 在全球范围内慢性感染超过 2.4 亿人,导致慢性肝炎、肝硬化和肝细胞癌 (HCC)。使用 CRISPR/Cas9 进行基因组编辑可以提供新的治疗方法,因为它可以直接破坏 HBV 基因组。然而,由于 HBV 基因组序列高度多样化,长度为 20 个核苷酸的向导 RNA (gRNA) 的相同目标序列在异质患者的靶 HBV DNA 中不一定完整存在。因此,可能的基因组编辑药物仅对有限数量的患者有效。在这里,我们表明可以一步构建携带八个多重 gRNA 表达单元的腺病毒载体 (AdV),并扩增至足以进行体内研究而不缺失的水平。使用这种 AdV,在来自异质患者的 HepG2 细胞染色体中整合的 HBV X 基因在多个位点被切割并破坏。实际上,由于序列不匹配,八个靶标中有四个不能被切割,但其余四个靶标被切割,产生不可逆转的缺失。因此,多样化的 X 基因以超过 90%的效率被破坏。含有八个多重 gRNA 单元的 AdV 不仅提供了多个基因的敲除,而且还可以解决基因组编辑治疗中的异质靶标和逃逸突变体的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/aa1b04ca0025/ijms-22-10570-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/bcd65ddf9764/ijms-22-10570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/7c3694758382/ijms-22-10570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/aa1b04ca0025/ijms-22-10570-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/bcd65ddf9764/ijms-22-10570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/7c3694758382/ijms-22-10570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/8508944/aa1b04ca0025/ijms-22-10570-g003.jpg

相似文献

1
Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.腺病毒载体表达 CRISPR/Cas9 的八个多重引导 RNA 可有效破坏来自不同患者的乙型肝炎病毒基因。
Int J Mol Sci. 2021 Sep 29;22(19):10570. doi: 10.3390/ijms221910570.
2
Construction of adenovirus vectors simultaneously expressing four multiplex, double-nicking guide RNAs of CRISPR/Cas9 and in vivo genome editing.构建同时表达 CRISPR/Cas9 的四个多重、双切口向导 RNA 的腺病毒载体及体内基因组编辑。
Sci Rep. 2021 Feb 17;11(1):3961. doi: 10.1038/s41598-021-83259-0.
3
Construction and Stability of All-in-One Adenovirus Vectors Simultaneously Expressing Four and Eight Multiplex Guide RNAs and Cas9 Nickase.同时表达四个和八个多重向导 RNA 和 Cas9 尼克酶的一体式腺病毒载体的构建和稳定性。
Int J Mol Sci. 2024 Aug 12;25(16):8783. doi: 10.3390/ijms25168783.
4
The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.CRISPR-Cas 在清除乙型肝炎病毒共价闭合环状 DNA 中的潜力和挑战。
Virus Res. 2018 Jan 15;244:304-310. doi: 10.1016/j.virusres.2017.06.010. Epub 2017 Jun 13.
5
CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.CRISPR/Cas9 系统双 gRNA 协同抑制乙型肝炎病毒复制。
Discov Med. 2024 Jun;36(185):1169-1179. doi: 10.24976/Discov.Med.202436185.107.
6
Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.开发一种体内递送系统,用于 CRISPR/Cas9 介导的靶向乙型肝炎病毒cccDNA。
Virus Res. 2020 Dec;290:198191. doi: 10.1016/j.virusres.2020.198191. Epub 2020 Oct 10.
7
Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.利用 CRISPR/Cas 介导的基因编辑治疗乙型肝炎病毒和丙型肝炎病毒感染的研究进展。
Virus Res. 2018 Jan 15;244:311-320. doi: 10.1016/j.virusres.2017.01.003. Epub 2017 Jan 10.
8
Highly multiplex guide RNA expression units of CRISPR/Cas9 were completely stable using cosmid amplification in a novel polygonal structure.采用新型多边形结构的 cosmid 扩增技术,可实现 CRISPR/Cas9 中高度多重靶向的 guide RNA 表达单元的完全稳定。
J Gene Med. 2019 Nov;21(11):e3115. doi: 10.1002/jgm.3115. Epub 2019 Oct 29.
9
CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.CRISPR-Cas9 靶向乙型肝炎病毒共价闭合环状 DNA 可产生转录活跃的附加体变异体。
mBio. 2022 Apr 26;13(2):e0288821. doi: 10.1128/mbio.02888-21. Epub 2022 Apr 7.
10
Short term but highly efficient Cas9 expression mediated by excisional system using adenovirus vector and Cre.腺病毒载体和 Cre 介导的切除系统实现的短期但高效的 Cas9 表达。
Sci Rep. 2021 Dec 21;11(1):24369. doi: 10.1038/s41598-021-03803-w.

引用本文的文献

1
The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.病毒性肝炎向肝细胞癌的恶性转化:机制与干预措施
MedComm (2020). 2025 Mar 8;6(3):e70121. doi: 10.1002/mco2.70121. eCollection 2025 Mar.
2
Emerging Gene-editing nano-therapeutics for Cancer.新兴的用于癌症治疗的基因编辑纳米疗法
Heliyon. 2024 Oct 20;10(21):e39323. doi: 10.1016/j.heliyon.2024.e39323. eCollection 2024 Nov 15.
3
Construction and Stability of All-in-One Adenovirus Vectors Simultaneously Expressing Four and Eight Multiplex Guide RNAs and Cas9 Nickase.

本文引用的文献

1
Construction of adenovirus vectors simultaneously expressing four multiplex, double-nicking guide RNAs of CRISPR/Cas9 and in vivo genome editing.构建同时表达 CRISPR/Cas9 的四个多重、双切口向导 RNA 的腺病毒载体及体内基因组编辑。
Sci Rep. 2021 Feb 17;11(1):3961. doi: 10.1038/s41598-021-83259-0.
2
HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals.HBV 进化和遗传变异:对预防、治疗和抗病毒药物开发的影响。
Antiviral Res. 2021 Feb;186:104973. doi: 10.1016/j.antiviral.2020.104973. Epub 2020 Nov 6.
3
The evolution and clinical impact of hepatitis B virus genome diversity.
同时表达四个和八个多重向导 RNA 和 Cas9 尼克酶的一体式腺病毒载体的构建和稳定性。
Int J Mol Sci. 2024 Aug 12;25(16):8783. doi: 10.3390/ijms25168783.
4
Construction and application of adenoviral vectors.腺病毒载体的构建与应用
Mol Ther Nucleic Acids. 2023 Sep 9;34:102027. doi: 10.1016/j.omtn.2023.09.004. eCollection 2023 Dec 12.
5
Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges.通过 CRISPR/Cas 靶向 miRNA 治疗癌症:优势与挑战。
Mil Med Res. 2023 Jul 17;10(1):32. doi: 10.1186/s40779-023-00468-6.
6
Optimization of CRISPR-Cas system for clinical cancer therapy.用于临床癌症治疗的CRISPR-Cas系统的优化
Bioeng Transl Med. 2022 Dec 23;8(2):e10474. doi: 10.1002/btm2.10474. eCollection 2023 Mar.
7
Development of therapeutic vaccines for the treatment of diseases.用于疾病治疗的治疗性疫苗的研发。
Mol Biomed. 2022 Dec 8;3(1):40. doi: 10.1186/s43556-022-00098-9.
8
Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics.腺病毒载体:作为抗乙肝病毒疫苗和治疗药物的潜力。
Genes (Basel). 2022 Oct 25;13(11):1941. doi: 10.3390/genes13111941.
9
Advantages of CRISPR-Cas9 combined organoid model in the study of congenital nervous system malformations.CRISPR-Cas9联合类器官模型在先天性神经系统畸形研究中的优势。
Front Bioeng Biotechnol. 2022 Sep 2;10:932936. doi: 10.3389/fbioe.2022.932936. eCollection 2022.
乙型肝炎病毒基因组多样性的演变及其临床影响。
Nat Rev Gastroenterol Hepatol. 2020 Oct;17(10):618-634. doi: 10.1038/s41575-020-0296-6. Epub 2020 May 28.
4
Adenovirus vectors in hematopoietic stem cell genome editing.腺相关病毒载体在造血干细胞基因组编辑中的应用。
FEBS Lett. 2019 Dec;593(24):3623-3648. doi: 10.1002/1873-3468.13668. Epub 2019 Nov 20.
5
Highly multiplex guide RNA expression units of CRISPR/Cas9 were completely stable using cosmid amplification in a novel polygonal structure.采用新型多边形结构的 cosmid 扩增技术,可实现 CRISPR/Cas9 中高度多重靶向的 guide RNA 表达单元的完全稳定。
J Gene Med. 2019 Nov;21(11):e3115. doi: 10.1002/jgm.3115. Epub 2019 Oct 29.
6
Hepatitis B virus X protein enhances the development of liver fibrosis and the expression of genes associated with epithelial-mesenchymal transitions and tumor progenitor cells.乙型肝炎病毒 X 蛋白增强肝纤维化的发展和与上皮-间充质转化及肿瘤祖细胞相关基因的表达。
Carcinogenesis. 2020 May 14;41(3):358-367. doi: 10.1093/carcin/bgz109.
7
Human immunity to Cas9.人类对Cas9的免疫反应。
Nat Methods. 2019 Apr;16(4):286. doi: 10.1038/s41592-019-0385-z.
8
Identification of preexisting adaptive immunity to Cas9 proteins in humans.鉴定人类对 Cas9 蛋白的预先存在的适应性免疫。
Nat Med. 2019 Feb;25(2):249-254. doi: 10.1038/s41591-018-0326-x. Epub 2019 Jan 28.
9
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population.成人人群中普遍存在对化脓性链球菌 Cas9 反应性 T 细胞。
Nat Med. 2019 Feb;25(2):242-248. doi: 10.1038/s41591-018-0204-6. Epub 2018 Oct 29.
10
Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption.成对的 D10A Cas9 切口酶有时比单个核酸酶更有效地用于基因破坏。
Nucleic Acids Res. 2018 Jul 6;46(12):e71. doi: 10.1093/nar/gky222.